AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis

European Journal of Pharmacology

Volumn 542, Issue 1-3, 2006, Pages 100-105

  Kim, Kathline ^a   Moore, Dan H ^a   Makriyannis, Alexandros ^b   Abood, Mary E ^a  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^b NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Amyotrophic lateral sclerosis; Cannabinoid; Neuroinflammation

Indexed keywords

(2 IODO 5 NITROBENZOYL) [1 (1 METHYLPIPERIDIN 2 YLMETHYL) 1H INDOLE 3 YL]METHANONE; 3 (2 IODO 5 NITROBENZOYL) 1 (1 METHYL 2 PIPERIDINYLMETHYL)INDOLE; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AGONIST; UNCLASSIFIED DRUG; CANNABINOID; SOD1 G93A PROTEIN; SUPEROXIDE DISMUTASE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DISEASE COURSE; DISEASE MODEL; DRUG EFFICACY; DRUG SELECTIVITY; DRUG TOLERABILITY; FEMALE; MALE; MATHEMATICAL MODEL; MOTOR DYSFUNCTION; MOUSE; NONHUMAN; PARALYSIS; PRIORITY JOURNAL; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; SURVIVAL; TASK PERFORMANCE; TRANSGENIC MOUSE; TREMOR; WEIGHT REDUCTION; WILD TYPE; AMINO ACID SUBSTITUTION; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; DRUG POTENTIATION; GENETICS; HUMAN; KAPLAN MEIER METHOD; MOTOR ACTIVITY; MUTATION; PATHOPHYSIOLOGY; SEX DIFFERENCE;

AMINO ACID SUBSTITUTION; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; CANNABINOIDS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MICE; MICE, TRANSGENIC; MODELS, MOLECULAR; MOTOR ACTIVITY; MUTATION; RECEPTOR, CANNABINOID, CB2; SEX FACTORS; SUPEROXIDE DISMUTASE;

EID: 33746261289     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.05.025     Document Type: Article

References (36)

1. Baker D., Pryce G., Croxford J., Brown P., Pertwee R., Huffman J., and Layward L. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 404 (2000) 84-87
2. 2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. J. Neurosci. 23 (2003) 11136-11141
3. Brown Jr. R.H. Amyotrophic lateral sclerosis. Insights from genetics. Arch. Neurol. 54 (1997) 1246-1250
4. Bruijn L., Becher M., Lee M., Anderson K., Jenkins N., Copeland N., Sisodia S., Rothstein J., Borchelt D., Price D., and Cleveland D. ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron 18 (1997) 327-338
5. 2 receptor-dependent mechanism. Mol. Pharmacol. 65 (2004) 999-1007
6. Carter G.T., and Rosen B.S. Marijuana in the management of amyotrophic lateral sclerosis. Am. J. Hosp. Palliat Care 18 (2001) 264-270
7. Cleveland D.W., and Rothstein J.D. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat. Rev., Neurosci. 2 (2001) 806-819
8. Gurney M., Pu H., Chiu A., Canto M.D., Polchow C., Alexander D., Caliendo J., Hentati A., Kwon Y., Deng H., Chen W., ZHai P., Sufit R., and Siddique T. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 264 (1994) 1772-1775
9. Gurney M.E., Cutting F.B., Zhai P., Doble A., Taylor C.P., Andrus P.K., and Hall E.D. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann. Neurol. 39 (1996) 147-157
10. 2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 10529-10533 (Electronic publication 12003 Aug 10513)
11. Kaplan E., and Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53 (1958) 457-481
12. Klein T.W. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat. Rev. Immunol. 5 (2005) 400-411
13. Klivenyi P., Ferrante R.J., Matthews R.T., Bogdanov M.B., Klein A.M., Andreassen O.A., Mueller G., Wermer M., Kaddurah-Daouk R., and Beal M.F. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat. Med. 5 (1999) 347-350
14. Lambrechts D., Storkebaum E., Morimoto M., Del-Favero J., Desmet F., Marklund S.L., Wyns S., Thijs V., Andersson J., van Marion I., Al-Chalabi A., Bornes S., Musson R., Hansen V., Beckman L., Adolfsson R., Pall H.S., Prats H., Vermeire S., Rutgeerts P., Katayama S., Awata T., Leigh N., Lang-Lazdunski L., Dewerchin M., Shaw C., Moons L., Vlietinck R., Morrison K.E., Robberecht W., Van Broeckhoven C., Collen D., Andersen P.M., and Carmeliet P. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat. Genet. 34 (2003) 383-394
15. Lee S.Y., Oh S.M., and Chung K.H. Estrogenic effects of marijuana smoke condensate and cannabinoid compounds. Toxicol. Appl. Pharmacol. 22 (2006) 22
16. Ludolph A.C., Meyer T., and Riepe M.W. The role of excitotoxicity in ALS-what is the evidence?. J. Neurol. 247 (2000) I7-I16
17. McGeer P.L., and McGeer E.G. Inflammatory processes in amyotrophic lateral sclerosis. Muscle Nerve 26 (2002) 459-470
18. Nicholson S.J., Witherden A.S., Hafezparast M., Martin J.E., and Fisher E.M. Mice, the motor system, and human motor neuron pathology. Mamm. Genome 11 (2000) 1041-1052
19. Panikashvili D., Simeonidou C., Ben-Shabat S., Hanus L., Breuer A., Mechoulam R., and Shohami E. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 413 (2001) 527-531
20. Pertwee R. Cannabis and cannabinoids: pharmacology and rationale for clinical use. Forsch. Komplement.med. 6 Suppl 3 (1999) 12-15
21. Pinheiro J.C., and Bates D.M. Mixed-Effects Models in S and S-PLUS (2000), Springer, New York
22. 2 cannabinoid receptors. Anesthesiology 99 (2003) 955-960
23. Raman C., McAllister S.D., Rizvi G., Patel S.G., Moore D.H., and Abood M.E. Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid. Amyotroph. Lateral Scler. Other Mot. Neuron Disord. 5 (2004) 33-39
24. Ramirez B.G., Blazquez C., Gomez del Pulgar T., Guzman M., and de Ceballos M.L. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J. Neurosci. 25 (2005) 1904-1913
25. Robberecht W. Oxidative stress in amyotrophic lateral sclerosis. J. Neurol. 247 (2000) I1-I6
26. Rosen D., Siddique T., Patterson D., Figlewicz D., Sapp P., Hentati A., Donaldson D., Goto J., O'Regan J., Deng H., Rahmani Z., Krizus A., McKenna-Yasek D., Cayabyab A., Gaston S., Berger R., Tanzi R., Halperin J., Herzfeldt B., Bergh R.V.d., Hung W.-Y., Bird T., Deng G., Mulder D., Smyth C., Laing N., Soriano E., Pericak-Vance M., Haines J., Rouleau G., Gusella J., Horvitz Jr. H., and R.B. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362 (1993) 59-62
27. Stella N. Cannabinoid signaling in glial cells. Glia 48 (2004) 267-277
28. Trieu V.N., and Uckun F.M. Genistein is neuroprotective in murine models of familial amyotrophic lateral sclerosis and stroke. Biochem. Biophys. Res. Commun. 258 (1999) 685-688
29. Veldink J.H., Bar P.R., Joosten E.A., Otten M., Wokke J.H., and van den Berg L.H. Sexual differences in onset of disease and response to exercise in a transgenic model of ALS. Neuromuscul. Disord. 13 (2003) 737-743
30. 1 receptors in cannabinoid anticonvulsant effects. Eur. J. Pharmacol. 428 (2001) 51-57
31. Walter L., Franklin A., Witting A., Wade C., Xie Y., Kunos G., Mackie K., and Stella N. Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J. Neurosci. 23 (2003) 1398-1405
32. Weydt P., Hong S.Y., Kliot M., and Moller T. Assessing disease onset and progression in the SOD1 mouse model of ALS. Neuroreport 14 (2003) 1051-1054
33. Weydt P., Yuen E.C., Ransom B.R., and Moller T. Increased cytotoxic potential of microglia from ALS-transgenic mice. Glia 48 (2004) 179-182
34. Weydt P., Hong S., Witting A., Moller T., Stella N., and Kliot M. Cannabinol delays symptom onset in SOD1 (G93A) transgenic mice without affecting survival. Amyotroph. Lateral Scler. Other Mot. Neuron Disord. 6 (2005) 182-184
35. Wong P., Pardo C., Borchelt D., Lee M., Copeland N., Jenkins N., Sisodia S., Cleveland D., and Price D. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 14 (1995) 1105-1116
36. Zhu S., Stavrovskaya I.G., Drozda M., Kim B.Y., Ona V., Li M., Sarang S., Liu A.S., Hartley D.M., Wu du C., Gullans S., Ferrante R.J., Przedborski S., Kristal B.S., and Friedlander R.M. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 417 (2002) 74-78